I TO I
DEAD

Serial Number

97657739

Owner

Nona Biosciences US, Inc.

Attorney

Eric Lamb

Filing Date

Nov 1, 2022

Add to watchlist:

No watchlists yet
View on USPTO

I TO I Trademark

Serial Number: 97657739

I TO I is a trademark filed by Nona Biosciences US, Inc. on November 1, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Nona Biosciences US, Inc. (9 trademarks)

Suite 355
Natick, MA 01760

Entity Type: 03

Trademark Details

Filing Date

November 1, 2022

Registration Date

Not Registered

Published for Opposition

January 30, 2024

Goods & Services

Diagnostic preparations for medical purposes; Drug delivery agents in the form of powders, tablets, capsules, solutions, cells and nanoparticles that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Tumor suppressing agents; Pharmaceutical products for the prevention and treatment of cancer; Medicines for the prevention and treatment of immune system related diseases and disorders, cancer, infections, endocrine system related diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, cardiovascular diseases and disorders, musculoskeletal diseases and disorders, tumor; Pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders, cancer, infections, endocrine system related diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, cardiovascular diseases and disorders, musculoskeletal diseases and disorders, tumor; Chemical preparations for pharmaceutical or medical purposes, namely, for the prevention and treatment of immune system related diseases and disorders, cancer, infections, endocrine system related diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, cardiovascular diseases and disorders, musculoskeletal diseases and disorders, tumor; Biological preparations for the prevention and treatment of immune system related diseases and disorders, cancer, infections, endocrine system related diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, cardiovascular diseases and disorders, musculoskeletal diseases and disorders, tumor; Biochemical medicines for the prevention and treatment of immune system related diseases and disorders, cancer, infections, endocrine system related diseases and disorders, metabolic diseases and disorders, neurological diseases and disorders, cardiovascular diseases and disorders, musculoskeletal diseases and disorders, tumor

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 30, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 30, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 28, 2025 EXRA
CORRECTED NOA E-MAILED
Jun 27, 2025 NOAC
SOU EXTENSION 1 GRANTED
Jun 27, 2025 EX1G
DIVISIONAL PROCESSING COMPLETE
Jun 27, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 26, 2025 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 4, 2024 AITU
DIVISIONAL REQUEST RECEIVED
Sep 24, 2024 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Sep 24, 2024 ERTD
SOU TEAS EXTENSION RECEIVED
Sep 24, 2024 EEXT
SOU EXTENSION 1 FILED
Sep 23, 2024 EXT1
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 26, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 30, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 30, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 10, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 27, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 26, 2023 CRFA
ASSIGNED TO LIE
Dec 26, 2023 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 31, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 26, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 26, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 26, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 17, 2022 NWOS
NEW APPLICATION ENTERED
Nov 4, 2022 NWAP